These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 20335122

  • 1. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
    Cai YL, Zheng YM, Cheng JR, Wang W, Zhang YN, Wang WH, Wu YS, Zhong WM, Li J, Mo YK.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
    [Abstract] [Full Text] [Related]

  • 2. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
    Xia C, Zhu K, Zheng G.
    Int J Clin Exp Pathol; 2015 Mar; 8(12):16104-10. PubMed ID: 26884888
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
    Cai YL, Li J, Lu AY, Zheng YM, Zhong WM, Wang W, Gao JQ, Zeng H, Cheng JR, Tang MZ.
    Asian Pac J Cancer Prev; 2014 Mar; 15(5):2001-6. PubMed ID: 24716925
    [Abstract] [Full Text] [Related]

  • 4. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
    Liu Y, Huang Q, Liu W, Liu Q, Jia W, Chang E, Chen F, Liu Z, Guo X, Mo H, Chen J, Rao D, Ye W, Cao S, Hong M.
    Int J Cancer; 2012 Jul 15; 131(2):406-16. PubMed ID: 21866545
    [Abstract] [Full Text] [Related]

  • 5. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL, Chen H, Peng SG, Lin JH, Huang PY.
    Zhonghua Yi Xue Za Zhi; 2013 Nov 26; 93(44):3516-9. PubMed ID: 24521892
    [Abstract] [Full Text] [Related]

  • 6. [Combined detection of Epstein-Barr virus antibodies for serodiagnosis of nasopharyngeal carcinoma].
    Cai YL, Zheng YM, Wang W, Wei Y, Shen XX, Cheng JR, Wu YS, Gao JQ, Zhong WM, Li J.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec 26; 30(12):2746-8. PubMed ID: 21177196
    [Abstract] [Full Text] [Related]

  • 7. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, Kusumo H, Zeng YS, Schouten T, Mubarika S, Middeldorp JM.
    J Clin Microbiol; 2006 Apr 26; 44(4):1459-67. PubMed ID: 16597877
    [Abstract] [Full Text] [Related]

  • 8. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
    Tiwawech D, Srivatanakul P, Karaluk A, Ishida T.
    Asian Pac J Cancer Prev; 2003 Apr 26; 4(2):113-8. PubMed ID: 12875623
    [Abstract] [Full Text] [Related]

  • 9. [Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression].
    Cai YL, Zheng YM, Cheng JR, Li J, Mo YK, Zhong QY.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct 26; 23(5):384-7. PubMed ID: 20387494
    [Abstract] [Full Text] [Related]

  • 10. [Six anti-Epstein-Barr virus antibodies in healthy adults in a high risk area of nasopharyngeal carcinoma].
    Yi B, Gu YL, Zong YS, Cheng WM, Ji MF.
    Ai Zheng; 2009 Aug 26; 28(8):822-6. PubMed ID: 19664327
    [Abstract] [Full Text] [Related]

  • 11. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.
    Cancer; 2004 Mar 15; 100(6):1162-70. PubMed ID: 15022282
    [Abstract] [Full Text] [Related]

  • 12. Rta-IgG as a biomarker for diagnosis and post treatment prognostic of nasopharyngeal carcinoma.
    Xu XF, Lu RQ, Xiao R, Zhou L, Zhao XM, Hu XC, Gao X, Guo L.
    Cancer Biomark; 2016 Mar 15; 16(3):467-76. PubMed ID: 27062704
    [Abstract] [Full Text] [Related]

  • 13. The serological diagnostic value of EBV-related IgA antibody panels for nasopharyngeal carcinoma: a diagnostic test accuracy meta-analysis.
    Liu H, Lei L, Song S, Geng X, Lin K, Li N, Chen W, Peng J, Ren J.
    BMC Cancer; 2024 Sep 07; 24(1):1115. PubMed ID: 39244576
    [Abstract] [Full Text] [Related]

  • 14. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
    Guo J, Cui Z, Zheng Y, Li X, Chen Y.
    Pathol Oncol Res; 2020 Oct 07; 26(4):2185-2190. PubMed ID: 32222897
    [Abstract] [Full Text] [Related]

  • 15. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects.
    Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, Ng MH, Middeldorp JM.
    J Infect Dis; 2004 Jul 01; 190(1):53-62. PubMed ID: 15195243
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
    Yao JJ, Lin L, Jin YN, Wang SY, Zhang WJ, Zhang F, Zhou GQ, Cheng ZB, Qi ZY, Sun Y.
    Cancer Sci; 2017 Aug 01; 108(8):1640-1647. PubMed ID: 28603915
    [Abstract] [Full Text] [Related]

  • 17. [Prognostic significance of serum anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma].
    Cai YL, Li J, Lu AY, Zhong WM, Zheng YM, Gao JQ, Zeng H, Chen WS, Liang W, Tang MZ.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Apr 01; 27(2):119-22. PubMed ID: 24044217
    [Abstract] [Full Text] [Related]

  • 18. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.
    Dardari R, Khyatti M, Benider A, Jouhadi H, Kahlain A, Cochet C, Mansouri A, El Gueddari B, Benslimane A, Joab I.
    Int J Cancer; 2000 Apr 01; 86(1):71-5. PubMed ID: 10728597
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
    Chen H, Chi P, Wang W, Li L, Luo Y, Fu J, Zhang L, Liu W.
    Int J Infect Dis; 2014 Aug 01; 25():110-5. PubMed ID: 24878579
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.